loading
전일 마감가:
$0.3098
열려 있는:
$0.3126
하루 거래량:
962.12K
Relative Volume:
0.93
시가총액:
$19.47M
수익:
-
순이익/손실:
$-22.83M
주가수익비율:
-0.3814
EPS:
-0.79
순현금흐름:
$-20.87M
1주 성능:
+0.43%
1개월 성능:
+26.07%
6개월 성능:
-57.04%
1년 성능:
-81.96%
1일 변동 폭
Value
$0.2933
$0.314
1주일 범위
Value
$0.2933
$0.3352
52주 변동 폭
Value
$0.2223
$2.535

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name
명칭
Cognition Therapeutics Inc
Name
전화
412-481-2210
Name
주소
2403 SIDNEY STREET, PITTSBURGH
Name
직원
25
Name
트위터
Name
다음 수익 날짜
2024-08-08
Name
최신 SEC 제출 서류
Name
CGTX's Discussions on Twitter

CGTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CGTX
Cognition Therapeutics Inc
0.3012 19.47M 0 -22.83M -20.87M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
451.48 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
536.76 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
552.05 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.50 28.51B 3.81B -644.79M -669.77M -6.24

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-19 업그레이드 B. Riley Securities Neutral → Buy
2024-07-30 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2021-11-03 개시 B. Riley Securities Buy
2021-11-03 개시 Oppenheimer Outperform

Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스

pulisher
Jun 17, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jun 17, 2025
pulisher
Jun 14, 2025

Two Sigma Investments LP Boosts Stock Position in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 03, 2025

Cognition Therapeutics (CGTX) Secures Donation to Support Dement - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Cognition Therapeutics Launches Expanded Access Program for Zervimesine - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Major Breakthrough: Donor Funds New Treatment Access for Lewy Body Dementia Patients - Stock Titan

Jun 03, 2025
pulisher
Jun 02, 2025

B. Riley Expects Reduced Earnings for Cognition Therapeutics - Defense World

Jun 02, 2025
pulisher
May 30, 2025

HC Wainwright Issues Positive Forecast for CGTX Earnings - Defense World

May 30, 2025
pulisher
May 28, 2025

Alzheimer's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com

May 28, 2025
pulisher
May 28, 2025

Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World

May 28, 2025
pulisher
May 28, 2025

Cognition Therapeutics Releases New Episode of - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Lewy Body Dementia Caregivers Share Powerful Stories Alongside Leading Neurologists in New Medical Podcast - Stock Titan

May 28, 2025
pulisher
May 27, 2025

CGTX: HC Wainwright & Co. Lowers Price Target While Maintaining Buy Rating | CGTX Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Exp - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Expected Equity Dilution | CGTX Stock News - GuruFocus

May 27, 2025
pulisher
May 23, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 23, 2025
pulisher
May 10, 2025

Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World

May 10, 2025
pulisher
May 09, 2025

Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Cognition announces outcomes from trial of zervimesine for geographic atrophy - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Cognition Therapeutics Inc (NASDAQ: CGTX) Stock Price Forecast: $100 - Stocksregister

May 09, 2025
pulisher
May 09, 2025

Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025 - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Cognition Therapeutics Presented Data at Association for - GlobeNewswire

May 09, 2025
pulisher
May 09, 2025

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - Stock Titan

May 09, 2025
pulisher
May 09, 2025

zervimesine shows promise in dry AMD trial - Investing.com

May 09, 2025
pulisher
May 09, 2025

Cognition Therapeutics Reports Q1 2025 Financials and Progress - TipRanks

May 09, 2025
pulisher
May 08, 2025

Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics - Ophthalmology Times

May 08, 2025
pulisher
May 08, 2025

zervimesine shows promise in dry AMD trial By Investing.com - Investing.com South Africa

May 08, 2025
pulisher
May 08, 2025

Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial - HCPLive

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics Announces Positive Phase 2 Trial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - Santé log

May 08, 2025
pulisher
May 08, 2025

Ratio Examination: Cognition Therapeutics Inc (CGTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Cognition Therapeutics (CGTX) Stock Target Lowered by Chardan Ca - GuruFocus

May 08, 2025
pulisher
May 07, 2025

COGNITION THERAPEUTICS INC SEC 10-Q Report - TradingView

May 07, 2025
pulisher
May 07, 2025

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Cognition Therapeutics, Inc. Advances Alzheimer’s and DLB Programs with FDA Meeting Request and Upcoming Presentations at AAIC and ARVO - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides ... - Bluefield Daily Telegraph

May 07, 2025
pulisher
May 07, 2025

Caregiver Distress The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters - Clinical Leader

May 07, 2025
pulisher
May 04, 2025

Geode Capital Management LLC Raises Holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World

May 04, 2025
pulisher
Apr 28, 2025

CES ENERGY SOLUTIONS CORP. ANNOUNCES AMENDMENT AND EXTENSION TO ITS INCREASED CREDIT FACILITY - The Globe and Mail

Apr 28, 2025
pulisher
Apr 28, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World

Apr 28, 2025
pulisher
Apr 25, 2025

Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com

Apr 25, 2025
pulisher
Apr 18, 2025

CGTX Stock Sees Surge of Approximately 16.59% in Last Five Days - knoxdaily.com

Apr 18, 2025
pulisher
Apr 11, 2025

Dry AMD Therapeutics Market Size in 7MM is expected to grow at - openPR.com

Apr 11, 2025
pulisher
Apr 09, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN

Apr 09, 2025
pulisher
Apr 08, 2025

Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com

Apr 08, 2025

Cognition Therapeutics Inc (CGTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.79
price up icon 0.65%
$35.66
price down icon 0.89%
$21.34
price up icon 0.16%
$98.25
price down icon 2.23%
$108.80
price up icon 2.21%
biotechnology ONC
$245.50
price up icon 1.42%
자본화:     |  볼륨(24시간):